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ttp://dx.doi.org/10.1016/j.jmoldx.2013.08.004Recent years have seen development and implementation of anticancer therapies targeted to particular
gene mutations, but methods to assay clinical cancer specimens in a comprehensive way for the critical
mutations remain underdeveloped. We have developed UW-OncoPlex, a clinical molecular diagnostic
assay to provide simultaneous deep-sequencing information, based on >500 average coverage, for all
classes of mutations in 194 clinically relevant genes. To validate UW-OncoPlex, we tested 98 previously
characterized clinical tumor specimens from 10 different cancer types, including 41 formalin-ﬁxed
parafﬁn-embedded tissue samples. Mixing studies indicated reliable mutation detection in samples with
10% tumor cells. In clinical samples with 10% tumor cells, UW-OncoPlex correctly identiﬁed 129 of
130 known mutations [sensitivity 99.2%, (95% CI, 95.8%e99.9%)], including single nucleotide vari-
ants, small insertions and deletions, internal tandem duplications, gene copy number gains and am-
pliﬁcations, gene copy losses, chromosomal gains and losses, and actionable genomic rearrangements,
including ALK-EML4, ROS1, PML-RARA, and BCR-ABL. In the same samples, the assay also identiﬁed
actionable point mutations in genes not previously analyzed and novel gene rearrangements of MLL and
GRIK4 in melanoma, and of ASXL1, PIK3R1, and SGCZ in acute myeloid leukemia. To best guide existing
and emerging treatment regimens and facilitate integration of genomic testing with patient care, we
developed a framework for data analysis, decision support, and reporting clinically actionable results.
(J Mol Diagn 2014, 16: 56e67; http://dx.doi.org/10.1016/j.jmoldx.2013.08.004)Supported by the Department of Defense Ovarian Cancer Research Pro-
gram OC093285 (T.W.) and NIH grant R01CA157744 (T.W. and M.-C.K.).
C.C.P. and S.J.S. contributed equally to this work.The era of precision oncology began in 1998 with the
approval of the anti- human epidermal growth factor receptor
2 (HER2) monoclonal antibody, trastuzumab, for the treat-
ment of HER2-positive breast cancer.1 At the same time, an
immunohistochemistry-based diagnostic test (HercepTest;
Dako, Glostrup, Denmark) was approved for the identiﬁca-
tion of tumors that express HER2, necessary to ascertain
which patients are eligible for trastuzumab treatment. This
advance was followed by the introduction of erlotinib, a
small molecule tyrosine kinase inhibitor against epidermal
growth factor receptor (EGFR), which has proven useful instigative Pathology
.patients with non-small cell lung cancer with activating
EGFRmutations.2e4 More recently, two U.S. Food and Drug
Administrationeapproved drugs that also require a genomic
sequence-based companion diagnostic have advanced into
late-stage clinical trials: vemurafenib, which targets meta-
static malignant melanoma harboring the BRAF V600E
mutation5 , and crizotinib, which has shown efﬁcacy against
Targeted Deep Sequencing by UW-OncoPlexnon-small cell lung cancers that have ALK rearrangements.6
Clinical trials for additional agents directed against speciﬁc
genes or mutations are currently underway, and are expected
to progressively increase the repertoire of targeted cancer
therapies available.
These successes and accumulated discoveries of potential
cancer driver mutations through the use of exome and whole-
genome sequencing7e12 raise important questions about the
long-term practicality of existing clinical diagnostics for the
molecular characterization of cancers. As new targeted
therapies are approved for molecular subtypes, and more
genes with prognostic value are identiﬁed, the number of
single-gene tests needed to adequately classify a tumor sub-
type increases, with the consequences of potentially
exhausting available tissue specimens and of driving up
health care costs. Yet, despite the concerns for increased risk
and health care expense associated with additional tissue
acquisition for molecular testing, validated clinical di-
agnostics suitable for assaying multiple genes and different
classes of mutations in a multiplexed fashion remain lacking.
Most currently available multiplexed clinical assays examine
only a limited number of speciﬁc sites in a relatively small
number of genes.13,14 More recently, next-generation
sequencing assays have been developed for detecting
cancer-associated mutations in clinical specimens in a more
comprehensive manner, but these assays have only been
validated on a small number of tumor types (breast, colon,
and prostate).15e17 As assays of this type become more
widespread, a framework for identifying, interpreting, and
reporting actionable variants will be required for this tech-
nology to reach its full potential as a clinical diagnostic test.
Here, we describe our development and clinical valida-
tion of a targeted massively parallel sequencing assay for
194 cancer-relevant genes, UW-OncoPlex, designed as a
comprehensive diagnostic test for mutational events of all
types in an efﬁcient and cost-effective manner. The assay is
intended to allow the most complete and informative mo-
lecular characterization of a wide variety of clinical speci-
mens, and is scalable to large numbers of additional genes in
the future. Our assay improves on earlier approaches, most
importantly by expanding the spectrum of mutations
detectable to include complex genomic rearrangements and
copy number variants (CNVs), in addition to greater
sensitivity for all variants. We also develop an accompa-
nying data interpretation and decision support network to
inform patient prognoses and therapeutic options.
Materials and Methods
DNA Samples
DNA samples used for validation experiments were derived
from 98 different tissue samples, including colon cancer,
melanoma, acute myeloid leukemia (AML), myeloproliferative
disorders, chronic myeloid leukemia, lung cancer, gastroin-
testinal stromal tumor, and other neoplasms (SupplementalThe Journal of Molecular Diagnostics - jmd.amjpathol.orgTable S1). All samples had prior molecular characterization
of one or more mutations by a clinically validated targeted
assay(s) in a Clinical Laboratory Improvement Amend-
mentsecertiﬁed laboratory. Clinical testing was performed
using a combination of Sanger sequencing (KIT, MPL,
PDGFRA, RUNX1), melting-curve analysis (BRAF, EGFR
p.L858R, IDH1, IDH2, KRAS ), allele-speciﬁc PCR (JAK2,
BCR-ABL), ﬂuorescence in situ hybridization (ALK, MLL,
PML-RARA, ROS1), capillary electrophoresis fragment length
polymorphism [CEBPA, EGFR exon 19 insertions and de-
letions (indels), FLT3-ITD], and DNAmicroarray (single-gene
and chromosomal-scale deletions). Solid tissue samples (nZ
41) were formalin-ﬁxed, parafﬁn-embedded (FFPE); samples
from hematological malignancies (nZ 57) were fresh frozen
cells from peripheral blood or bone marrow. DNA was
extracted from all sample types using the Gentra Puregene
DNA Isolation Kit (Catalog #158489; Qiagen, Valencia, CA).
H&E-stained slides were reviewed before DNA extraction for
all FFPE samples, andwhen feasible, macrodissection of tumor
areas was performed to enrich tumor cellularity. Tumor cellu-
larity in macrodissected areas was estimated by review of
H&E-stained slides for FFPE specimens or quantiﬁed by ﬂow
cytometry for hematological specimens. No tumor enrichment
was performed for hematological malignancy samples. Esti-
mation of tumor cellularity was not available for eight samples
(Supplemental Table S1). Collectively, these 98 samples
comprised a validation panel that included multiple known
single nucleotide variant (SNV), indel, translocation, inversion,
and copy number variation (CNV) mutations. In addition,
HapMap DNAs for NA12878 (selected as a reference sample)
and NA18545 (selected because of a known heterozygous
BCL2L11 intron 2 deletion polymorphism) were obtained from
Coriell Cell Repositories (Camden, NJ). Clinical specimens
were obtained in accordance with the declaration of Helsinki
and the ethics guidelines of the human subjects division of the
University of Washington and the University of Chicago.
For mixing studies, control DNA was derived from pe-
ripheral blood lymphocytes of a normal control subject.
Before mixing, real-time PCRwas performed on each sample
to ensure the DNA quality/PCR ampliﬁcation efﬁciency was
equal for both the patient sample and diluent DNA.
Library Construction, Gene Capture, and Massively
Parallel Sequencing
Sequencing libraries were prepared from DNA samples as
described elsewhere.18 When available, 3 mg of DNA was
used. The minimum input requirement was 750 ng of DNA,
which did not result in loss of assay performance. For
samples at or near the minimum input requirement, addi-
tional pre-capture PCR cycles (up to 10 cycles in total) were
performed to generate the 500 ng required for hybridization.
Libraries were hybridized to a custom design of comple-
mentary RNA (cRNA) biotinylated oligonucleotides tar-
geting the exons of 194 genes (Table 1 and Supplemental
Table S2) and select introns of genes involved in genomic57
Pritchard et alrearrangements (Supplemental Table S3), for a total of
>850 kb of targeted DNA. Post-capture PCR incorporated
primers containing a unique 6-bp index as performed pre-
viously,18 allowing multiplexing of multiple samples onto
the same sequencing lane.
DNA sequencing was performed on a HiSeq2000
sequencing system (Illumina, San Diego, CA) with 2  101-
bp, paired-end reads as described,18 and on aMiSeq (Illumina)
with 2  150-bp, paired-end reads according to the manu-
facturer’s instructions. The average fraction of on-target reads
was 0.423. The minimum gene-level average coverage was set
to 50, with genes below this threshold reported as failed. The
minimum acceptable average coverage for the entire panel was
set at 150, and the minimum library complexity (the fraction
of unique DNA fragments sequenced) was set at 20%. Up to
24 samples were multiplexed onto a single lane of the HiSeq
sequencer (average of 540 coverage after removal of
duplicate reads) (Figure 1), or up to two samples were multi-
plexed for a MiSeq run (average of 512 coverage after
removal of duplicate reads) (Figure 1).
Data Analysis
The data analysis pipeline is diagrammed in Figure 1. Initial
read mapping against the human reference genome (hg19/Table 1 Gene Panel
Tier 1: Currently
actionable
Tier 2: Actionable in the
near future
ABL1 KIF5B ABL2 MAPK1
AKT1 KIT AKT2 MC1R
ALK KRAS AKT3 MCL1
ASXL1 MAP2K1 ATM MDM2
AURKA MET AURKB MDM4
BAP1 MLL BCOR MEN1
BCR KRAS CBL MITF
BCL2L11 MPL CBLB MLH1
BRAF NKX2-1 CDK6 MRE11A
BRCA1 NPM1 CHEK1 MSH2
BRCA2 NRAS CHEK2 MSH6
CCND1 PDGFRA ERBB3 MYC
CCNE1 PIK3CA ERBB4 MYCN
CDK4 PML FBXW7 NF2
CDK8 PTEN FGFR1 NOTCH1
CEBPA RARA FLT1 PAX5
DDR2 ROS1 FLT4 PDGFRB
DNMT3A RET GATA2 PIK3R1
EGFR STK11 GNA11 PMS2
EML4 TP53 GNAQ RAF1
EPHB2 VHL GRM3 RUNX1
ERBB2 HDAC4 SMO
FGFR2 HRAS SRSF2
FGFR4 IGF1R SUZ12
FLT3 IKZF1 TSC1
HIF1A JAK3 TSC2
IDH1 KDM6A TET2
IDH2 KDR TYR
JAK2 MAP2K2 WT1
58GRCh37) and alignment processing was performed using
BWA version 0.6.1-r104 (http://sourceforge.net/projects/
bio-bwa/ﬁles, last accessed November 28, 2011)19 and
SAMtools version 0.1.18 (http://sourceforge.net/projects/
samtools/ﬁles, last accessed September 2, 2011),20 respec-
tively. Sample-level, fully local indel realignment was then
performed using GATK version 1.621 (Broad Institute,
Cambridge, MA). Duplicate reads were removed using
PICARD version 1.72 (http://picard.sourceforge.net, last
accessed December 5, 2011). Quality score recalibration
was then performed using GATK. This realigned and
recalibrated alignment was used for all subsequent analyses.
SNV and indel calling was performed through the GATK
Universal Genotyper using default parameters and VarScan
version 2.3.2 (http://sourceforge.net/projects/varscan, last
accessed October 31, 2011).22 For indel calling through
VarScan, the minimum variant frequency was set to 0.01
reads, and the minimum number of variant reads was set to
4, whereas for SNV calling, the minimum variant frequency
was set to 0.03, and the minimum number of variant reads
was set to 5, with default parameters for all other settings.
We found that GATK variant calls supported by high-
quality scores (>500) were also identiﬁed by VarScan.
Variants of interest called by VarScan alone were some-
times accepted, but because of the algorithm’s relatively lowTier 3: Frequently
mutated
Germline
pharmacogenomics
APC PTCH1 ABCB1 SLC22A2
BAK1 PTPN11 ABCC2 SLCO1B3
BCL2 PTPRD ABCC4 SOD2
CDH1 RB1 ABCG2 SULT1A1
CDKN2A RICTOR C1orf144 TPMT
CREBBP RPS14 COMT TYMS
CRLF2 SF1 CYP1B1 UGT1A1
CSF1R SF3B1 CYP2C19 UMPS
CTNNB1 SMAD2 CYP2C8
EPHA3 SMAD3 CYP2D6
EPHA5 SMAD4 CYP3A4
EPHB6 SMARCA4 CYP3A5
ETV6 SMARCB1 DPYD
EZH2 SPRY4 EIF3A
FGFR3 SRC ERCC2
GAB2 TFG ESR1
GATA1 TGFBR2 ESR2
GNAS TRRAP FCGR1A
GRIN2A U2AF1 FCGR2A
HNF1A U2AF65 FCGR3A
IL7R ZRSR2 GSTP1
JAK1 GUCY1A2
MAP2K4 ITPA
MUTYH LRP2
MYCL1 MAN1B1
NF1 MTHFR
NOTCH2 NQO1
PBRM1 NRP2
PRPF40B SLC22A1
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Figure 1 Scheme showing the data analysis pipeline. QA, quality assurance.
Targeted Deep Sequencing by UW-OncoPlexspeciﬁcity, such calls were limited to speciﬁc known
actionable mutations or to indel mutations >3 bp in length
that were supported by four or more variant reads passing
the population frequency ﬁlters (as described below). Var-
iants identiﬁed by VarScan alone were manually reviewed
at the laboratory director level using the Integrated Geno-
mics Viewer23 version 5.64 (Broad Institute) to assess the
quality of base calls, the mapping quality for the reads, and
the overall read depth at the site.
PINDEL version 0.2.424 was used to identify tandem
duplications and indels >10 bp in length. Structural variants
were identiﬁed using CREST version 1.0.25
For CNV analysis, copy number states for individual probes
were initially called using CONTRA version 2.0.3 (http://
sourceforge.net/projects/contra-cnv/ﬁles, last accessed July
24, 2012)26 with reference to a CNV control comprising reads
from two independent rounds of library preparation and
sequencing of the HapMap individual NA12878. CNV calls
were made at the resolution of individual exons using custom
Perl scripts. On a gene-by-gene basis, read-depth statistics
were calculated from baits originating in the same exon.
Adjacent exons were merged into larger segments if the read
depths of their component baits were not signiﬁcantly different
(P> 0.0001) by Student’s t-test, and read-depth statistics were
recalculated for the larger segments. Segments were required
to have an average adjusted log2 ratio compared to the refer-
ence sample of 0.3 to be considered as a possible CNV
event. To facilitate identiﬁcation ofmeaningful segments, each
segment was also evaluated using a score, calculated by
multiplying the number of bases in the segment by the absoluteThe Journal of Molecular Diagnostics - jmd.amjpathol.orgvalue of the average adjusted log2 ratio, and by which higher-
scoring segments tended to be more credible than lower-
scoring segments. CNV plots were visualized using the R
package ggplot2 (http://ggplot2.org, last accessed August 15,
2012),27 with graphical overlay of segments having average
adjusted log2 ratios 0.3 and scores exceeding 1500. We
deﬁned copy number gain as a predicted copy number of 3 or
4, and ampliﬁcation as a predicted copy number of 5 or higher.
SNV and indel data were annotated with gene-based
annotation, conservation scores, predicted effects at the pro-
tein level, and population frequency using ANNOVAR
(BIOBASE, Wolfenbüttel, Germany),28 and output from
other programs was annotated and formatted using custom
scripts to facilitate review. ANNOVAR was also used to
annotate the frequency of variants in a database obtained
from sequencing of patients internally. We initially ﬁltered
variant calls based on population frequency data from both
the 1000 Genomes project29 and our internal variant fre-
quency database, excluding variants (other than clinically
ﬂagged variants) occurring in greater than 1% of any popu-
lation as likely germline variation or recurrent sequencing
artifact. Clinically important mutations that are suspected to
be germline based on allelic ratio, or based on prior genetics
knowledge (such as a known founder mutation) are reported
with a statement indicating that if there is clinical suspicion
that mutation may be germline, additional testing is indicated.
The quality of sequencing libraries was routinely evaluated
on the basis of information about library complexity, sequence
read depth, and the fraction of reference variants in NA12878
(as described in Results) recovered in positive controls.59
Table 2 Limits of Mutation Detection for Three Variants
Sample
Variant reads at each dilution
FLT3-ITD NPM1 DNMT3A
Undiluted* 120 78 85
1:2 80 59 67
1:4 27 21 19
1:8 25 16 18
1:16 3 6 ND
Mutations: FLT3-ITD c.1804_1805ins24bp, NPM1 c.860_863dup, DNMT3A
c.1627G>T (p.G543C).
*45% tumor cellularity undiluted; acute myeloid leukemia (AML) sample
HEME49 used for mixing study.
ND, not detected.
Pritchard et alGenomic Microarray Analysis
For validation of CNV calling, seven FFPE samples and one
HEME sample were tested in parallel by genomic micro-
array (Supplemental Table S1). Samples were characterized
using SurePrint G3 Cancer CGHþSNP 4180K microarray
(Agilent Technologies, Santa Clara, CA) with probes tar-
geting 657 cancer-associated genes and genomic regions
and probes tiled across the genome to allow proﬁling of
DNA copy number and copy neutral aberrations, such as
loss of heterozygosity, according to the manufacturer’s
protocols. Samples were normalized against manufacturer-
provided sex-matched reference standards (HapMap sam-
ples NA12891 and NA12878).
Results
Selection of the Gene Panel
Genes included in UW-OncoPlex were chosen to meet
criteria for one of three tiers corresponding to current clin-
ical actionability (Table 1). Tier 1 genes harbor mutations
that are currently clinically actionable, either by providing
information about sensitivity or resistance to speciﬁc tar-
geted therapies or by providing prognostic information
related to patient outcome. Tier 2 genes are expected to be
actionable in the near future, with targeted therapies
currently under active development in clinical trials. Tier 3
genes are recognized as recurrently mutated in cancers, but
robust prognostic information or targeted therapies are not
yet available. We assigned each gene to the lowest tier in
which it fulﬁlled requirements for one or more cancers.
Additionally, we included a panel of genes inﬂuencing drug
metabolism and clearance. Because of the less well-deﬁned
therapeutic implications of variants in these genes, we are
not yet reporting results from this part of the panel.
Construction of a Tumor Sequencing Data Analysis
Pipeline
We formulated a data analysis pipeline (Figure 1) based
on the Genome Analysis Toolkit (GATK) best practices
guidelines (http://www.broadinstitute.org/gatk/guide/best-
practices, last accessed December 19, 2011), following rec-
ommended methods for genome alignment and recalibration
before variant calling. Although GATK includes software
tools able to robustly identify SNVs and indels, it employs a
Bayesian likelihood model to predict genotype, which as-
sumes a diploid genome. This model is problematic for tumor
DNA, which may demonstrate a skewed allele balance sec-
ondary to a variety of factors. Indeed, in experimental sam-
ples, we found GATK variant calling alone was insufﬁcient
to reliably identify some variants in experimental tumor
samples, and therefore, we added a more sensitive genotype-
calling algorithm, VarScan, which identiﬁes any variant in a
heuristic fashion if there are sufﬁcient supporting reads.3060Identifying variants by two separate approaches allows for
redundancy, and thus robustness. To facilitate interpretation
and review of called variants, SNVs and indels were anno-
tated with respect to functional effects and population fre-
quencies. We integrated additional software tools to identify
other forms of genomic variation aside from SNVs and
relatively small indels. PINDEL24 has previously proven
useful in detecting otherwise difﬁcult-to-call internal tandem
duplications (ITD) in FLT331 and was therefore used in our
study as a means to identify both ITD and large indels
(exceeding 10 bases in length). Genomic structural variants,
including translocations, inversions, and large deletions,
were identiﬁed using CREST,25 which reanalyzes partially
mapped (soft-clipped) reads to identify sequence fragments
resulting from genomic rearrangements. Copy number vari-
ation was performed with CONTRA26 and a series of custom
segmentation and visualization scripts. Integration of these
genomic analysis techniques into the same analysis pipeline
allows for identiﬁcation of all types of genetic mutations
found in cancers.
Limit of Detection
An important consideration of the assay is the successful
detection of low-level mutations in patient samples. Even
after tumor enrichment steps such as macrodissection, pa-
tient samples are still usually a heterogeneous mixture of
tumor and non-neoplastic cells derived from surrounding
tissue or from reactive inﬁltrate, which may skew the rep-
resentation of mutant alleles. Further, cancers are hetero-
geneous in nature,32 and a mutation of interest may exist in
only a subset of tumor cells.
To evaluate the limit of mutation detection for UW-
OncoPlex, we performed serial mixing studies of tumor
DNA with non-neoplastic control DNA and determined how
effectively various forms of known heterozygous mutations
were recovered over a range of serial dilutions (Table 2). A
4-bp insertion mutation in NPM1 was detectable at the
highest tumor dilution examined (1:16), which represented
approximately 3% tumor cells because the starting sample
had 45% tumor cellularity. FLT3-ITD was also successfully
identiﬁed at the limits of detection for the highest tumorjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 3 Validation of Previously Known Mutations in 98 Clinical Samples
Mutation class Gene/region Mutation
Mutations recovered
Tumor cellularity 10% Tumor cellularity <10%*
SNV BRAF p.V600E 8/8
SNV BRAF p.V600K 2/2
SNV CEBPA p.E59X 1/1
SNV EGFR p.L858R 5/5 0/1
SNV IDH1 Codon 132 5/5 1/1
SNV IDH2 p.R140Q 4/4
SNV JAK2 p.V617F 1/1 5/6
SNV KIT p.K638E 1/1
SNV KIT p.D812Y 1/1
SNV KIT p.D816V 0/1
SNV KRAS Codon 12 or 13 5/5 2/2
SNV MPL p.W515L 1/1
SNV PDGFRA p.D842V 2/2
SNV RUNX1 p.Y260X 1/1y
Indel CEPBA C-terminal ins 2/2 0/1
Indel EGFR Exon 19 del 4/4
Indel EGFR Exon 19 ins 1/1
Indel EGFR Exon 20 ins 1/1
Indel FLT3 Tandem dup (ITD) 23/24z 3/5
Indel KIT Exon 11 del/ins 3/3
Indel NPM1 p.W288Cfs*12 20/20 4/4
CNV AKT2 Amplification 1/1
CNV BCL2L11 2.9-kb del intron 2 1/1y
CNV BRAF Copy gain 1/1
CNV CDKN2A Copy loss 3/3
CNV Chr1, 2, 3, 6, 15, 18, 22 Copy losses 1/1
CNV Chr1 Copy gain 1/1
CNV Chr7 Copy loss 2/2
CNV Chr8 Trisomy 1/1
CNV Chr9 Copy loss 1/1
CNV Chr14 Trisomy 1/1
CNV ChrX Copy loss 1/1
CNV EGFR Copy gain 1/1
CNV FGFR1 Copy gain 3/3
CNV GNAQ Copy loss 1/1
CNV HIF1A Copy loss 1/1
CNV MDM2 Amplification 1/1
CNV MET Copy gain 2/2
CNV MITF Copy gain 1/1
CNV MYC Copy gain 1/1
CNV PIK3CA Copy gain 1/1
CNV SMAD4 Copy loss 1/1
CNV SMO Copy gain 1/1
SV ALK-EML4 Gene fusion 5/5
SV BCR-ABL Gene fusion 1/1
SV MLL-MLLT3 Gene fusion 2/2 0/2
SV PML-RARA Gene fusion 2/2
SV ROS1 Gene inversion 1/1
Total 129/130 16/24
Sensitivity 99.2% 67%
(95% CI) (95.8%e99.9%) (47%e82%)
*<10% cellularity includes samples with unknown tumor cellularity.
yMutations in these two samples were germline.
zThe FLT3-ITD mutation not recovered was detected by capillary electrophoresis at an allelic ratio of 0.03, suggesting the mutation was present in only a
small subset of tumor cells.
SV, structural variation.
Targeted Deep Sequencing by UW-OncoPlex
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Figure 2 Copy number variants (CNVs) detec-
tion directly by UW-OncoPlex sequencing. Adjusted
log2 ratio of read depth of sequencing data are
plotted for individual baits (y axis) across captured
genomic regions (x axis). Overlaid horizontal black
lines indicate genomic microarray results in the
target regions for the same sample, illustrating
high concordance of CNV detection between UW-
OncoPlex and genomic microarray. Ampliﬁcations
or deletions of speciﬁc genes are indicated
(boxes), with corresponding array CGH calls
highlighted (arrowheads). Depicted are examples
from a melanoma (FFPE06) and colon cancer
sample (FFPE02).
Pritchard et aldilution tested (1:16). An SNV mutation in DNMT3A was
detectable at a 1:8 dilution of tumor to normal DNA, but
was not found at the 1:16 dilution. The limit of detection
was therefore at approximately 6% tumor cellularity,
although the precise limit of detection at each locus is likely
to be inﬂuenced by aneuploidy and by other factors such as
GC content and variation in read depth. We therefore
conservatively estimate that the assay is capable of reliably
recovering a heterozygous mutation when present in >10%
of cells in the original sample. A separate mixing study
using an FFPE sample harboring an EGFR exon 19 deletion
mutation produced similar results (Supplemental Table S4).
Sensitivity
We ﬁrst evaluated the performance of UW-OncoPlex
against a panel of clinical samples containing known mu-
tations of various types, including point mutations (SNVs),
indels, CNVs, and gene rearrangements. All mutations had
been previously identiﬁed through routine clinical testing
(Table 3 and Supplemental Table S1). When restricting the
analysis to the 82 samples with 10% tumor cellularity,
deep sequencing identiﬁed 90 of 91 [98.9% (95% CI,
94.0%e99.8%)] of expected SNV and indel mutations
previously identiﬁed by single-gene testing methods
(Table 3). The single missed mutation was a FLT3-ITD
approximately 72-bp insertion variant in an AML sample
(Supplemental Table S1). Although the sample had 22%
blasts by ﬂow cytometry, the FLT3-ITD was detected at a62very low allelic ratio of 0.03 by capillary electrophoresis,
suggesting that the mutation was present in only a small
subset of tumor cells.
Importantly, in samples with 10% tumor cellularity the
assay detected known structural variants, including gene
rearrangements validated by ﬂuorescence in situ hybridiza-
tion and CNVs measured by array genomic hybridization
(Table 3 and Figure 2). All known CNV events [28 of 28,
100% (95% CI, 88%e100%)] were recovered, including the
BCL2L11 (BIM) 2.9-kb intron 2 deletion polymorphism that
is associated with tyrosine kinase inhibitor resistance, and
gene ampliﬁcations of AKT2 and MDM2 (Figure 2).33 All
known gene rearrangements [11 of 11, 100% (95% CI,
74%e100%)] were accurately recovered, including ﬁve
ALK-EML4 rearrangements, two PML-RARA gene fusions,
two MLL-MLLT3 gene fusions, one ROS1 inversion, and
one BCR-ABL gene fusion (Table 3).
Among the 17 samples with <10% or unknown tumor
cellularity, the assay detected 16 of 24 known mutations
[67% (95% CI, 47%e82%)] (Table 3). On the basis of these
results and the limit of detection analysis, we established a
threshold of 10% tumor cellularity for samples to be run on
the assay.
Libraries prepared from FFPE material in this study did
not differ substantially from those prepared from fresh DNA
either with respect to the sensitivity of mutations recovered,
the average sequencing read depth, or the fraction of on
target reads. However, in some samples, FFPE-derived
DNA required several more PCR cycles to generatejmd.amjpathol.org - The Journal of Molecular Diagnostics
Targeted Deep Sequencing by UW-OncoPlexadequate material for gene capture than an equivalent
amount of DNA derived from fresh tissue, suggesting var-
iable amounts of sample degradation in FFPE samples. It is
expected that very highly degraded FFPE specimens would
prove unsuitable for sequencing.Comparison to a Reference Sample NA12878
To evaluate the performance characteristics of UW-
OncoPlex against a well-characterized reference sample,
we compared the variants detected for HapMap sample
NA12878 against variants detected and analyzed indepen-
dently by exome re-sequencing on the Illumina platform
(1000 Genomes data set) and by whole-genome sequencing
on the Complete Genomics platform (Complete Genomics
data set), which uses entirely different sequencing chemis-
tries. Within the regions targeted by UW-OncoPlex, 152
SNVs appeared in both published data sets. UW-OncoPlex
analysis recovered 149 of 152 of these SNVs. The three
variants not detected by UW-OncoPlex were all synony-
mous variants in NOTCH2. Given the number of paralogous
sequences for this gene, we suspect these reported variants
may represent false-positive results in both the 1000 Ge-
nomes and Complete Genomics datasets. In fact, at one of
these three sites (chr1:120539837), only one read matched
the SNV reported in the other data sets, with a mapping
quality of zero.
In all, 149 credible SNVs were called in common by our
pipeline and the two published data sets. In subsequent
experiments, we used these variants as a quality control
measure by evaluating their recovery in NA12878 as our
run-speciﬁc control sample. We required that at least 148 of
149 variants were recovered in NA12878 for the run to be
considered in control.The Journal of Molecular Diagnostics - jmd.amjpathol.orgReproducibility
To evaluate the reproducibility of the assay, we generated
multiple sequencing libraries from HapMap sample
NA12878 and analyzed them on eight separate sequencing
runs. All 149 credible variants for NA12878 were detected
in each run. In addition, repeat libraries were generated from
a subset of 34 patient samples and sequenced on a separate
HiSeq run by a different user, and all known mutations were
successfully recovered (Supplemental Table S1).
Speciﬁcity Analysis Based on Detection of Mutations
Not Previously Known
In the 98 samples in the validation series, UW-OncoPlex
revealed more than 200 potentially actionable mutations that
were not already known because the mutation region(s)
were not previously tested. We estimated analytic speciﬁcity
for UW-OncoPlex by conﬁrmatory Sanger sequencing on a
subset of these samples with mutations not previously
known to be present. We examined 17 variants in three
genes, and in all cases (17 of 17), Sanger sequencing vali-
dated the variant, yielding 100% speciﬁcity (95% CI, 82%e
100%) (Supplemental Figures S1, S2, and S3 and
Supplemental Table S5).
Detection of Novel Gene Rearrangements
In the 98 samples in the validation series, UW-OncoPlex
also revealed three novel gene rearrangements (Figure 3). In
an AML sample, we detected a rearrangement predicted to
disrupt the ﬁnal exon (exon 12) of ASXL1 by transposing it
into intergenic DNA. In a second AML specimen, we
detected a translocation involving PIK3R1 and SGCZ pre-
dicted to result in disruption of both genes. In a melanomaFigure 3 Novel gene rearrangements detected.
Chromosomal ideograms, gene-level schematics of
events, and conﬁrmatory bidirectional Sanger
sequencing are displayed for three chromosomal
rearrangements. Predicted sequences of rear-
rangements inferred from genomic sequence data
are displayed above electropherograms, with exact
chromosomal breakpoints indicated (Hg19 co-
ordinates). UTR, untranslated region.
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Pritchard et alsample, we detected a translocation involving MLL and
GRIK4, also predicted to disrupt the coding sequence of
both genes. All three gene rearrangement events were
conﬁrmed by bidirectional Sanger sequencing.
For each of these rearrangements, only one of the two
genes was targeted for hybridization gene capture. These
results indicate that it is possible to identify gene rear-
rangements by deep sequencing if only one of the two
rearrangement partners is sequenced, greatly expanding the
number of structural rearrangements that are potentially
detectable by the assay.
Data Interpretation and Clinical Reporting
Next-generation sequencing uncovers large numbers of ge-
netic variants, which pose challenges in analyzing clinical
samples.34 To accurately interpret data from the UW-
OncoPlex assay and subsequently convey that information
to clinicians, we developed a framework for data interpre-
tation and reporting. We ﬁrst implemented a strategy to
systematically identify the most important genomic variants
and to interpret the potential for impacting patient prognosis
and therapy (Figure 4). Actionable SNV and indel variants
were evaluated ﬁrst as clinically ﬂagged variants, including
mutations targeted by conventional clinical testing (for
example, BRAF p.V600E), and which are speciﬁcally ﬂag-
ged by our data analysis pipeline. We next applied ﬁlters to
exclude variants likely to be inconsequential (synonymous
variants, variants in intergenic DNA, etc), and to remove
variants present at >1% frequency in the general population
(as surveyed by Exome Variant Server and 1000 Genomes
data). We also ﬁltered against frequency data from our own
internal database of genomic variants observed during UW-
OncoPlex testing, a strategy that has proven especially
valuable, both by providing robust population frequency
data for our speciﬁc patient population, and by eliminatingReport Written by Pathologist Lab Director
Reporting in Medical Record
Sequencing Tumor Board
Independent 
Variant List
Analysis Report
Integrated List for Tumor Board Review
Independent 
Variant List
Independent 
Variant List
Data Filtering by “Clinically Flagged Variants”, Variant Type, Exome Variant Server 
Frequency, 1000 Genomes Frequency, Internal Variant Frequency
Variant Database Mining in COSMIC, My Cancer Genome, OMIM, PubMed
(three reviewers)
Figure 4 Scheme showing the framework for variant interpretation and
reporting.
64recurrent sequencing or analysis artifacts. Variants of in-
terest were then evaluated using a combination of database
mining and literature review to further investigate the po-
tential clinical impact in the context of current medical
literature. CNV and structural rearrangement data were
similarly analyzed, but due to the sporadic nature of these
events, could only be examined on a case-by-case basis
without prior ﬁltering.
At least three expert reviewers from the tumor sequencing
board independently compiled lists of potentially reportable
variants and reviewed the quality of the data that were being
used to support the variant calls, by examining genotype
quality score metrics and evaluating base call quality and
mapping quality of primary sequence reads using the Inte-
grated Genomics Viewer, as appropriate. The reviewers next
surveyed the primary literature about the identiﬁed variants
to inform recommendations made to the ordering provider.
These independent lists were combined by the laboratory
director and returned to the board for group review. Once
the sequencing tumor board agreed on a ﬁnal list of
reportable variants, the lab director composed a formal
report for the medical record describing the variants detec-
ted, the clinical action associated with each variant, and a
short list of pertinent negative genes for which no mutations
were detected.
The turnaround time for the entire assay from specimen
acquisition to clinical reporting ranged from 2 to 8 weeks,
with an average of 5 weeks.Discussion
Continuing advances in cancer genomics and development
of targeted therapies have begun to shift clinical paradigms
from treating cancers of a speciﬁc type to treating cancers
with speciﬁc genetic lesions. For example, targeted thera-
pies exist for patients with lung cancers harboring mutations
of EGFR or ALK and ROS1 rearrangements. The ability to
proﬁle every cancer specimen for a comprehensive set of
clinically actionable mutations underpins the emerging
vision of individualized oncology, allowing effective cancer
treatments to be optimized on the basis of genotype alone.
To this end, we have developed a framework for compre-
hensively interrogating actionable and near-actionable mu-
tations in cancer samples using targeted gene capture and
next-generation DNA sequencing. The method is cost
effective and robust enough to integrate into routine clinical
care. In contrast to the ﬁxed content of commercial mutation
hotspot panels such as Ion AmpliSeq (Life Technologies,
Carlsbad, CA), our approach is more inclusive, interrogating
for a large panel of genes, all exons, and where appropriate,
intronic sequences frequently involved in gene rearrange-
ment events. In addition, our data analysis pipeline permits
detection of all classes of genomic mutation, from point
mutations to structural rearrangements. Detection is very
sensitive even in the context of tumor heterogeneity orjmd.amjpathol.org - The Journal of Molecular Diagnostics
Targeted Deep Sequencing by UW-OncoPleximpurity. Further, because this assay is comprehensive, we
anticipate that routine testing using this approach will prove
valuable as a discovery tool, permitting identiﬁcation of
additional mutations in speciﬁc cancer types that may
inform the development of new therapeutic agents or pro-
vide prognostic information.
UW-OncoPlex proved effective with heterogeneous
tumor samples, with very high sensitivity in samples with
10% tumor cellularity. In such samples, the assay recov-
ered 99.2% (129 of 130) of known mutations (95% CI,
95.8%e99.9%). In samples of <10% or unknown tumor
cellularity, the assay detected 67% (16 of 24) of mutations
(95% CI, 47%e82%). This highlights the critical role of the
pathologist in quality assessment of all samples before
clinical testing to ensure adequate tumor cellularity for ac-
curate sequencing results. In practice, we evaluate cellularity
of all samples before UW-OncoPlex testing and append a
caveat statement to reports for samples that are close to the
10% cellularity threshold (ie, between 10% and 20%
cellularity), indicating that false-negative results for the
specimen cannot be entirely excluded.
Conventional molecular testing for cancers requires prior
knowledge or assumptions about the speciﬁc mutations that
will be detected in a cancer of a particular type (eg, BRAF and
KRAS testing for colorectal cancers, EGFR and ALK-EML4
testing for lung cancers). It is increasingly becoming appre-
ciated that neoplasms may harbor mutations in genes classi-
cally found in tumors from different tissues of origin. Such
mutations may serve as targets for effective, but noncanonical
cancer therapies.35 Such unanticipated actionable mutations
may prove valuable in selecting patient therapy regimens, yet
current approaches to testing interrogate only sites that are
speciﬁcally requested. UW-OncoPlex sequencing recovered
many potentially actionable mutations in genes not targeted by
routine clinical testing algorithms (Supplemental Table S1).
Our ﬁndings illustrate the beneﬁt of a comprehensive approach
to cancer testing that provides genomic information about
clinically actionable mutations in an unbiased fashion.
In addition to previously undetected substitution and indel
mutations, sequencing of the validation samples revealed
several novel structural variant mutations, including three
novel gene rearrangements that may play an active role in
cancer development (Figure 4). In one AML specimen, a
rearrangement disrupting the ﬁnal exon (exon 12) of ASXL1
was detected. Disruptive point mutations and frameshifts in
ASXL1 exon 12 are found commonly inAML and are a marker
for poor prognosis.36 To the best of our knowledge, disruption
of ASXL1 by gene rearrangement has not previously been re-
ported. In another case of AML, we detected a translocation
involving SGCZ and the 30 untranslated region of PIK3R1.
SGCZ has a structural role in connecting cytoskeletal proteins
with the extracellular matrix.37 P1K3R1 mutations have been
implicated in diverse cancer types,38 typically gain-of-function
changes that activate oncogenic PI3K signaling, and rarely
dominant-negative mutations affecting PTEN stabilization.39
Disruption of the 30 untranslated region in this case mayThe Journal of Molecular Diagnostics - jmd.amjpathol.orgaffect mRNA stability or miRNA regulation of the transcript,
with subsequent impact on PI3K signaling. Lastly, in a mel-
anoma case, we detected a translocation involving MLL and
GRIK4, which disrupted the coding sequence of both genes.
MLL encodes a histone methyltransferase and is frequently
activated in AML by partial tandem duplication or by forming
gene fusions with over 100 translocation partners described to
date, but has not been previously implicated in melanoma.40,41
GRIK4 is a glutamate receptor.42 The oncogenic roles of
glutamate signaling pathways have become recently recog-
nized inmelanoma,43e45 and the functional signiﬁcance of this
fusion merits further investigation. The Sanger-validated re-
covery of unsuspected and/or unreported point mutations and
structural rearrangements in many samples highlights the use
of genomic diagnostic testing as a research and discovery tool.
To effectively communicate results, it was necessary to
develop robust strategies for interpreting and reporting vari-
ants identiﬁed by UW-OncoPlex. We adopted a strategy
(Figure 4) involving a small (three- to six-member) sequencing
tumor board that independently, then collaboratively, reviews
testing results. Our reporting strategy is labor intensive and
may not be practical for all laboratories, but we believe that the
redundancy that overreading provides is both important and
beneﬁcial to the task of variant interpretation for such highly
complex data. As such, we have instituted this strategy as our
standard, and havemade it a priority to complete these reviews
within a timeline compatible with clinical reporting.
Next-generation sequencing technologies hold consider-
able promise for transforming clinical molecular testing of
cancers, allowing comprehensive detection of actionable
mutations irrespective of cancer type. As new actionable
genes are identiﬁed, they can be added to subsequent itera-
tions of the UW-OncoPlex panel with rapid assay revalida-
tion, allowing the diagnostic to evolve as our knowledge of
relevant cancer mutations improves. We also look forward to
technical advancements that will further increase utility of the
assay. Improvements in next-generation sequencing plat-
forms and sequencing library preparation techniques46,47 will
further decrease costs and improve throughput and accuracy.
Novel data analysis tools may further improve the sensitivity
of the assay without enhancement to the underlying sequence
data itself. This study demonstrates that next-generation
sequencing assays such as UW-OncoPlex are already
capable of providing valuable predictive and prognostic in-
formation from clinical samples and can have an immediate
impact on patient care.Acknowledgments
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